Recombinant Protein Therapeutics CDMO Market: Insights and Market Forecast

The global recombinant protein therapeutics CDMO market is expected to reach USD 52.0 billion by 2030 and is expected to expand at a CAGR of 13.95% from 2024 to 2030, according to a new report by Grand View Research, Inc. Growing technological innovations about the development of novel recombinant protein therapeutics and rising research and development for biologics are anticipated to influence the recombinant protein therapeutics CDMO industry positively. The development of novel recombinant protein therapeutics has observed significant advancements due to various technological innovations.

Recombinant proteins are bioengineered proteins produced by introducing the gene encoding the desired protein into a host cell, typically a microorganism or a mammalian cell, to express and produce the protein of interest. Several protein engineering platform technologies are currently employed to enhance the circulating half-life, targeting the precision and functionality of novel therapeutic protein drugs. These technologies also aim to boost production yield and ensure product purity.

Besides, the biopharmaceutical industry has witnessed significant growth, with an increasing number of companies investing in research and development of biologics, including recombinant proteins. This growth has been facilitated by advancements in manufacturing technologies, including adopting single-use bioreactors and other innovative production methods. For instance, in January 2024, Eurofins CDMO Alphora, Inc. announced the successful completion of its pilot-scale biologics development facility. With an expansive area of 3,300 square feet, this facility is exclusively dedicated to developing and scaling monoclonal antibodies (mAbs) and other therapeutic proteins derived from mammalian sources.

Moreover, the global increase in the prevalence of chronic and complex diseases, such as cancer, autoimmune disorders, & metabolic diseases, has increased the demand for innovative and effective therapeutic options. Recombinant protein therapeutics offer a diverse range of candidates to address these complex medical conditions. For instance, based on estimates from the American Cancer Society, it is projected that in 2023, there will be approximately 1,958,310 new cases of cancer and 609,820 cancer-related deaths in the U.S. Furthermore, according to a research article published by Oxford University, in June 2022, the number of approved and marketed antibody therapies reached 162, nearly half of which (42.6%) were being developed for the treatment of cancer.

In March 2023, the U.S. FDA granted accelerated clearance to Incyte Corporation's retifanlimab-dlwr for the treatment of adult patients with metastatic or recurrent, locally advanced Merkel Cell Carcinoma (MCC). Besides, biological therapy in cancer supports repairing, stimulating, or enhancing the immune response. Therefore, many pharmaceutical & biopharmaceutical companies are willing to invest in cancer-related novel treatments. Such advancements collectively aim to achieve a higher yield of quality products.

Get a preview of the latest developments in the Recombinant Protein Therapeutics CDMO Market? Download your FREE sample PDF copy today and explore key data and trends. 

Recombinant Protein Therapeutics CDMO Market Report Highlights

• The others segment dominated the market in 2023. The segment growth is driven by increasing recombinant protein therapies as a safer option than plasma-derived products owing to the potential to reduce bloodborne transmission of infectious diseases

• Based on the source, mammalian systems held the largest market share of 67.4% in 2023 attributed to an increase in the adoption of mammalian systems for sourcing recombinant proteins. Mammalian cell culture systems offer advantages in producing complex proteins with appropriate post-translational modifications, making them suitable for a wide range of therapeutic applications

• Based on indication, the metabolic disorders segment held a market share of 21.8% in 2023. The segment is driven by a growing aging population, and robust demand for pharmaceutical industry, which has contributed to its prominence in this field

• North America dominated the market with a share of 38.5% in 2023. The region has a strong R&D infrastructure and a robust biopharmaceutical industry, which has contributed to the market growth. Furthermore, the U.S. has a sophisticated and well-developed manufacturing infrastructure for biopharmaceuticals, including recombinant protein therapeutics

Recombinant Protein Therapeutics CDMO Market Segmentation

Grand View Research has segmented the global recombinant protein therapeutics CDMO market based on type, source, indication, service type, end-use, and region:

Recombinant Protein Therapeutics CDMO By Type Outlook (Revenue, USD Million, 2018 - 2030)

• Growth Hormones

• Interferons

• Vaccines

• Immunostimulating Agents

• Others

Recombinant Protein Therapeutics CDMO By Source Outlook (Revenue, USD Million, 2018 - 2030)

• Mammalian Systems

• Microbial Systems

• Others

Recombinant Protein Therapeutics CDMO By Indication Outlook (Revenue, USD Million, 2018 - 2030)

• Oncology

• Infectious Diseases

• Immunological Disorders

• Metabolic Disorders

• Haematological Disorders

• Others

Recombinant Protein Therapeutics CDMO By Service Type Outlook (Revenue, USD Million, 2018 - 2030)

• Contract Manufacturing

• Contract Development

Recombinant Protein Therapeutics CDMO By End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical Companies

• Biotech Companies

• Others

Recombinant Protein Therapeutics CDMO By Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o U.K.

o Germany

o France

o Italy

o Spain

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

List of Key Players in the Recombinant Protein Therapeutics CDMO Market

• Richter-Helm BioLogics

• Lonza

• Catalent, Inc

• FUJIFILM Diosynth Biotechnologies

• WuXi Biologics

• Curia Global, Inc.

• Batavia Biosciences B.V.

• HALIX B.V.

• BIOVIAN

• Enzene Biosciences Ltd

Order a free sample PDF of the Recombinant Protein Therapeutics CDMO Market Intelligence Study, published by Grand View Research.